Organon Faces Lawsuit After Dividend Cut Sparks Outrage

In a dramatic turn of events, Organon & Co. finds itself embroiled in a class action lawsuit following a sharp decline in its stock price. The pharmaceutical company, known for its focus on women’s health, is accused of misleading investors with overly optimistic statements while allegedly concealing crucial information about its financial priorities. Between October 31, 2024, and April 30, 2025, Organon reportedly downplayed its aggressive debt reduction strategy, which took precedence over maintaining its regular quarterly dividends. This strategic shift, particularly after the acquisition of Dermavant, led to a staggering 70% cut in dividends, catching shareholders off guard.

The fallout was swift and severe. On May 1, 2025, the market reacted to the news with Organon’s stock plummeting over 27%, from $12.93 to $9.45 per share, in just one day. This significant loss has prompted shareholders to seek legal recourse, aiming to recover their investments.

For those who have suffered losses during this period, there is an opportunity to join the class action lawsuit without any cost or obligation. Affected investors are encouraged to visit the link provided to understand their rights and potential for recovery.

Leading the charge is Levi & Korsinsky LLP, a firm with a formidable reputation in securities litigation. With over two decades of experience and a proven track record of securing substantial settlements for shareholders, they stand ready to represent those impacted by Organon’s actions.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Home